1 Min Read
April 19 (Reuters) - Aurobindo Pharma Ltd
* Clarifies on news item "US FDA issues 5-6 'largely procedural' observations to Aurobindo Pharma's Unit-III"
* Says have been issued a form 483 with 6 observations
* Observations are all on procedural improvements
* Says none of observations related to data integrity Source text - (bit.ly/2omdvev) Further company coverage: